[go: up one dir, main page]

AU2001260400A1 - Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders - Google Patents

Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders

Info

Publication number
AU2001260400A1
AU2001260400A1 AU2001260400A AU2001260400A AU2001260400A1 AU 2001260400 A1 AU2001260400 A1 AU 2001260400A1 AU 2001260400 A AU2001260400 A AU 2001260400A AU 2001260400 A AU2001260400 A AU 2001260400A AU 2001260400 A1 AU2001260400 A1 AU 2001260400A1
Authority
AU
Australia
Prior art keywords
preventing
digestive disorders
treating digestive
hydrogenotrophic
strains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2001260400A
Other versions
AU2001260400B2 (en
Inventor
Annick Bernalier
Michel Renaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
4D Pharma PLC
Original Assignee
4D Pharma PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0006009A external-priority patent/FR2808689B1/en
Application filed by 4D Pharma PLC filed Critical 4D Pharma PLC
Publication of AU2001260400A1 publication Critical patent/AU2001260400A1/en
Application granted granted Critical
Publication of AU2001260400B2 publication Critical patent/AU2001260400B2/en
Assigned to INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE(INRA) reassignment INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE(INRA) Request for Assignment Assignors: DIGESTAR, INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE(INRA)
Assigned to Microbiota Company Limited reassignment Microbiota Company Limited Request for Assignment Assignors: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE(INRA)
Assigned to THE MICROBIOTA COMPANY LIMITED reassignment THE MICROBIOTA COMPANY LIMITED Request to Amend Deed and Register Assignors: Microbiota Company Limited
Assigned to 4D PHARMA PLC reassignment 4D PHARMA PLC Request for Assignment Assignors: THE MICROBIOTA COMPANY LIMITED
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

AU2001260400A 2000-05-11 2001-05-11 Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders Expired AU2001260400B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR00/06009 2000-05-11
FR0006009A FR2808689B1 (en) 2000-05-11 2000-05-11 USE OF HYDROGENOTROPHIC ACETOGENIC STRAINS FOR THE PREVENTION OR TREATMENT OF DIGESTIVE DISORDERS
PCT/FR2001/001426 WO2001085187A1 (en) 2000-05-11 2001-05-11 Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders

Publications (2)

Publication Number Publication Date
AU2001260400A1 true AU2001260400A1 (en) 2002-02-07
AU2001260400B2 AU2001260400B2 (en) 2006-10-26

Family

ID=8850107

Family Applications (2)

Application Number Title Priority Date Filing Date
AU6040001A Pending AU6040001A (en) 2000-05-11 2001-05-11 Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders
AU2001260400A Expired AU2001260400B2 (en) 2000-05-11 2001-05-11 Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU6040001A Pending AU6040001A (en) 2000-05-11 2001-05-11 Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders

Country Status (13)

Country Link
US (2) US7749494B2 (en)
EP (1) EP1280541B2 (en)
JP (1) JP5183848B2 (en)
AT (1) ATE322902T1 (en)
AU (2) AU6040001A (en)
CA (1) CA2411563C (en)
CY (1) CY1107467T1 (en)
DE (1) DE60118723T3 (en)
DK (1) DK1280541T4 (en)
ES (1) ES2262650T5 (en)
FR (1) FR2808689B1 (en)
PT (1) PT1280541E (en)
WO (1) WO2001085187A1 (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
JP4618970B2 (en) * 2002-08-02 2011-01-26 マルホ株式会社 Anal pressure reduction external preparation
US20060008511A1 (en) * 2004-07-08 2006-01-12 Jhy-Jhu Lin Probiotic products for pet applications
US7935334B2 (en) * 2005-07-07 2011-05-03 Imagilin Technologies, LLC Probiotics as alternative medicines against infectious diseases
DE102006062250A1 (en) * 2006-12-22 2008-06-26 Roland Saur-Brosch Use of a composition of minerals and / or vitamins and optionally acetogenic and / or butyrogenic bacteria for oral or rectal administration for the treatment and prevention of abdominal discomfort
EP2072053B1 (en) 2007-12-21 2012-11-07 Compagnie Gervais Danone Method for decreasing abdominal girth by administering a bifidobacterium bacteria
EP2130543A1 (en) 2008-06-05 2009-12-09 Compagnie Gervais Danone Method for decreasing borborygmi by administering a bifidobacterium bacteria
FI4032586T3 (en) 2010-02-01 2025-11-25 Ferring Microbiome Inc Bacteriotherapy for clostridium difficile colitis
WO2011151941A1 (en) 2010-06-04 2011-12-08 国立大学法人東京大学 Composition having activity of inducing proliferation or accumulation of regulatory t cell
BR112013002667B1 (en) * 2010-08-04 2020-02-04 Thomas Julius Borody intestinal flora transplantation compositions and methods for making and using them and devices for administering them
HK1253538A1 (en) * 2010-08-04 2019-06-21 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them
KR101805873B1 (en) * 2011-08-03 2018-01-10 한화케미칼 주식회사 A nanoparticles of surface-modified with monosaccharide phosphate or monosaccharide phosphate derivatives, its colloidal solution and use thereof
EP3610881A1 (en) 2011-03-09 2020-02-19 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
EP3569690B1 (en) 2011-12-01 2024-08-28 The University of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
CA3008794C (en) 2012-03-29 2021-03-16 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
RU2015140610A (en) 2013-03-14 2017-04-17 ТЕРАБАЙОМ, ЭлЭлСи DIRECTED DELIVERY TO THE GASTROINTESTINAL TRACT OF PROBIOTIC MICRO-ORGANISMS AND / OR THERAPEUTIC MEANS
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
WO2014197562A1 (en) 2013-06-05 2014-12-11 Rebiotix, Inc. Microbiota restoration therapy (mrt), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
MA41020A (en) 2014-11-25 2017-10-03 Evelo Biosciences Inc PROBIOTIC AND PREBIOTIC COMPOSITIONS, AND THEIR METHODS OF USE FOR MODULATION OF THE MICROBIOME
ES2658310T3 (en) 2014-12-23 2018-03-09 4D Pharma Research Limited A strain of thetaiotaomicron bacteroides and its use in reducing inflammation
EP3193901B1 (en) 2014-12-23 2018-04-04 4D Pharma Research Limited Pirin polypeptide and immune modulation
MX387737B (en) * 2015-02-27 2025-03-18 White Dog Labs Inc MIXOTROPHIC FERMENTATION METHOD FOR PRODUCING ACETONE, ISOPROPANOL, BUTYRIC ACID AND OTHER BIOPRODUCTS, AND MIXTURES THEREOF.
BR112017024265B1 (en) 2015-05-11 2022-08-09 Mybiotics Pharma Ltd METHODS FOR GROWING A BIOFILM OF PROBIOTIC BACTERIA IN SOLID PARTICLES
CN107949391B (en) 2015-05-14 2021-11-09 克雷斯顿沃控股公司 Compositions for fecal flora transplantation and methods for making and using them and devices for delivering them
PT3297644T (en) 2015-05-22 2022-03-30 Univ Arizona State Methods for treating autism spectrum disorder and associated symptoms
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
JP6616431B2 (en) 2015-06-09 2019-12-04 レビオティクス インコーポレイテッド Method for producing a microbiota recovery treatment (MRT) composition
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
MA55434B1 (en) 2015-06-15 2022-02-28 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41060B1 (en) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprising bacterial strains
PT3307288T (en) 2015-06-15 2019-10-17 4D Pharma Res Ltd Compositions comprising bacterial strains
TWI759266B (en) * 2015-06-15 2022-04-01 英商4D製藥研究有限公司 Use of compositions comprising bacterial strains
MA41010B1 (en) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprising bacterial strains
MA45287A (en) 2015-11-20 2018-08-22 4D Pharma Res Ltd COMPOSITIONS CONTAINING BACTERIAL STRAINS
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
PT3313423T (en) * 2016-03-04 2019-07-10 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
CA3025210A1 (en) 2016-05-25 2017-11-30 Mybiotics Pharma Ltd. Composition and methods for microbiota therapy
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
TWI802545B (en) * 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 Compositions comprising bacterial strains
GB201703548D0 (en) * 2017-03-06 2017-04-19 4D Pharma Plc Compositions comprising bacterial strains
GB201703552D0 (en) * 2017-03-06 2017-04-19 4D Pharma Plc Compositions comprising bacterial strains
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
GB201621123D0 (en) * 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
WO2018187467A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating parkinson's disease (pd) and related disorders
RS61872B1 (en) * 2017-05-22 2021-06-30 4D Pharma Res Ltd Compositions comprising bacterial strains
WO2018215782A1 (en) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strain
WO2018218159A1 (en) 2017-05-26 2018-11-29 Crestovo Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
JP6840272B2 (en) 2017-06-14 2021-03-10 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ Composition containing a bacterial strain
EP3638271B1 (en) 2017-06-14 2020-10-14 4D Pharma Research Limited Compositions comprising bacterial strains
RS63393B1 (en) 2017-06-14 2022-08-31 4D Pharma Res Ltd COMPOSITIONS CONTAINING BACTERIAL STRAINS
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
JP2021527639A (en) 2018-06-19 2021-10-14 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ Dosage form containing biotherapeutic products
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
TW202019447A (en) 2018-07-16 2020-06-01 英商4D製藥研究有限公司 Compositions comprising bacterial strains
CN113164527A (en) 2018-09-27 2021-07-23 芬奇治疗控股有限责任公司 Compositions and methods for treating epilepsy and related disorders
BR112021022501A2 (en) 2019-05-10 2021-12-28 4D Pharma Res Limited Compositions comprising bacterial strains
PE20221399A1 (en) 2019-07-19 2022-09-15 Finch Therapeutics Holdings Llc METHODS AND PRODUCTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
BR112022004032A2 (en) * 2019-09-05 2022-05-24 Superbrewed Food Inc Mixotrophic probiotic compositions and uses thereof in the treatment of abdominal distention
EP3839039A1 (en) 2019-12-16 2021-06-23 4D Pharma Research Limited Providing bacterial biomass with improved storage stability
TW202220639A (en) 2020-08-06 2022-06-01 英商４Ｄ製藥有限公司 Lyophilisation process
KR20230112700A (en) 2020-11-26 2023-07-27 4디 파마 레온, 에스.엘.유. method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443826A (en) * 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
AUPM823094A0 (en) 1994-09-16 1994-10-13 Goodman Fielder Limited Probiotic compositions
AUPM864894A0 (en) * 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
AUPN698495A0 (en) * 1995-12-06 1996-01-04 Pharma Pacific Pty Ltd Improved therapeutic formulation and method
JP4282763B2 (en) * 1996-03-20 2009-06-24 ザ、ユニバーシティ、オブ、ニュー、サウス、ウェイルズ Changes in the microbial population in the digestive tract
SE511524C2 (en) 1997-06-02 1999-10-11 Essum Ab Lactobacillus casei rhamnosus strain and pharmaceutical preparation for the control of pathogenic intestinal bacteria
DE19826928A1 (en) 1998-06-17 1999-12-23 Novartis Consumer Health Gmbh Medicines containing viable anaerobic bacteria that inhibit sulfate reduction by sulfate-reducing bacteria
AU5301399A (en) * 1998-08-20 2000-03-14 Miyarisan Pharmaceutical Co.,Ltd. Rugs comprising butyric acid-producing bacterium combined with bile acid component

Similar Documents

Publication Publication Date Title
AU2001260400A1 (en) Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
WO2001078781A8 (en) Methods for prevention and treatment of gastrointestinal disorders
AU2935200A (en) Compounds for the treatment of obesity
AU2001266068A1 (en) Treatment of mineral substrates
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU3791601A (en) Treatment of coal
AU2001239052A1 (en) Compositions for prevention and treatment of dementia
AU2002248269A1 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
AU2000276362A1 (en) Composition for the treatment of diabetes
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
AU2002237667A1 (en) Methods for the treatment and prevention of urinary stone disease
AU2001277534A1 (en) Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity
AU2001264522A1 (en) Methods and compositions for the prevention of myopia
AU1878201A (en) Composition for the treatment of damaged tissue
AU2021601A (en) Composition for the treatment of dandruff
AU2001232345A1 (en) Compositions for preventing and treating digestive diseases
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
AU5792398A (en) Leukotriene antagonists for treatment or inhibition of gout
AU2566201A (en) Compounds and methods for the treatment of pain
AU2420101A (en) Method and composition for the treatment of pain
AU4225500A (en) Methods and compositions for the treatment and prevention of lung disease